1. Home
  2. MXCT vs ENTX Comparison

MXCT vs ENTX Comparison

Compare MXCT & ENTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo MaxCyte Inc.

MXCT

MaxCyte Inc.

SELL

Current Price

$1.38

Market Cap

155.8M

Sector

Health Care

ML Signal

SELL

Logo Entera Bio Ltd.

ENTX

Entera Bio Ltd.

SELL

Current Price

$3.29

Market Cap

147.4M

Sector

Health Care

ML Signal

SELL

Company Overview

Basic Information
Metric
MXCT
ENTX
Founded
1999
2010
Country
United States
Israel
Employees
N/A
N/A
Industry
Biotechnology: Electromedical & Electrotherapeutic Apparatus
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Health Care
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
155.8M
147.4M
IPO Year
2021
2015

Fundamental Metrics

Financial Performance
Metric
MXCT
ENTX
Price
$1.38
$3.29
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
6
5
Target Price
$4.11
★ $9.75
AVG Volume (30 Days)
★ 1.4M
228.1K
Earning Date
11-10-2026
11-06-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
★ N/A
EPS
N/A
★ 0.33
Revenue
★ $33,026,000.00
$42,000.00
Revenue This Year
$4.77
N/A
Revenue Next Year
$10.06
N/A
P/E Ratio
★ N/A
$9.94
Revenue Growth
★ N/A
N/A
52 Week Low
$0.64
$0.91
52 Week High
$1.80
$4.20

Technical Indicators

Market Signals
Indicator
MXCT
ENTX
Relative Strength Index (RSI) 55.07 57.67
Support Level $1.02 $2.71
Resistance Level $1.54 $3.26
Average True Range (ATR) 0.14 0.17
MACD -0.01 0.00
Stochastic Oscillator 70.41 56.15

Price Performance

Historical Comparison
MXCT
ENTX

About MXCT MaxCyte Inc.

MaxCyte Inc is a life sciences company focused on advancing the discovery, development, and commercialization of next-generation cell therapies. It uses its proprietary cell engineering technology platform to support biotechnology and pharmaceutical customers in cell therapy, gene editing, immuno-oncology, and biologic development. It operates in one segment: cell engineering technology, which generates revenue mainly from product sales, licenses, research and clinical license fees, and program-related revenues as its SPL customers achieve development and regulatory milestones. Its platform, the ExPERT Platform, is based on Flow Electroporation technology designed to efficiently and safely modify human cells with high efficiency, low cytotoxicity, and scalability for clinical use.

About ENTX Entera Bio Ltd.

Entera Bio Ltd is a clinical-stage biopharmaceutical company engaged in the development of orally delivered macromolecule therapeutics, including peptides and therapeutic proteins. The company focuses on underserved, chronic medical conditions where oral administration of a mini tablet peptide or peptide replacement therapy has the potential to perform. Its product candidates are: EB613, which is being developed as an oral, osteoanabolic (bone-building) tablet treatment for osteoporosis; EB612, being developed as an oral PTH(1-34) tablet peptide replacement therapy for patients with hypoparathyroidism; EB618, an Oral GLP-1 being developed to tackle obesity; and Oral GLP-2, a peptide tablet alternative for patients suffering from short bowel syndrome. The company operates in Israel.

Share on Social Networks: